drugset / Trial / NCT02212067

A Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes

NCT02212067

Phase 1 Completed 87 enrolled Novo Nordisk A/S
RandomizedParallel-groupDouble-blindTreatment

Summary

This trial is conducted in Europe. The aim of the trial is to investigate the effects of semaglutide on ß-cell function in subjects with type 2 diabetes.

Timeline

Start
2014-08-11
Primary completion
2015-05-11
Completion
2015-05-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Semaglutide Peptide 1 mg Subcutaneous